-+ 0.00%
-+ 0.00%
-+ 0.00%

Oncoinvent 1H26 operating loss widens to NOK 68.99 million; revenue falls to NOK 8.2 million

PUBT·08/27/2026 05:02:38
Listen to the news
Oncoinvent 1H26 operating loss widens to NOK 68.99 million; revenue falls to NOK 8.2 million
  • Oncoinvent posted a 1H 2026 operating loss of NOK 68.99 million, widening from NOK 52.02 million a year earlier.
  • Revenue fell to NOK 8.2 million from NOK 11.96 million in 1H 2025.
  • Cash stood at NOK 108.84 million.
  • Reached 50% recruitment in its Phase 2 ovarian cancer study of Radspherin, adding four new clinical sites.
  • CEO Oystein Soug said recruitment momentum accelerated in the first half, reinforcing confidence in Radspherin’s potential in ovarian cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncoinvent ASA published the original content used to generate this news brief via Cision (Ref. ID: 202608270100BITN____UKPR__EN_20260826-BIT-2769-0) on August 27, 2026, and is solely responsible for the information contained therein.